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Introduction: Despite improvements in adjuvant therapy, late systemic recurrences remain a lethal consequence of both
early- and late-stage breast cancer. A delayed recurrence is thought to arise from a state of tumor dormancy, but the
mechanisms that govern tumor dormancy remain poorly understood.
Methods: To address the features of breast tumors associated with late recurrence, but not confounded by variations in
systemic treatment, we compiled breast tumor gene expression data from 4,767 patients and established a discovery cohort
consisting of 743 lymph node-negative patients who did not receive systemic neoadjuvant or adjuvant therapy. We
interrogated the gene expression profiles of the 743 tumors and identified gene expression patterns that were associated with
early and late disease recurrence among these patients. We applied this classification to a subset of 46 patients for whom
expression data from microdissected tumor epithelium and stroma was available, and identified a distinct gene signature in
the stroma and also a corresponding tumor epithelium signature that predicted disease recurrence in the discovery cohort. This
tumor epithelium signature was then validated as a predictor for late disease recurrence in the entire cohort of 4,767 patients.
Results:We identified a novel 51-gene signature from microdissected tumor epithelium associated with late disease
recurrence in breast cancer independent of the molecular disease subtype. This signature correlated with gene
expression alterations in the adjacent tumor stroma and describes a process of epithelial to mesenchymal transition
(EMT) and tumor-stroma interactions.
Conclusions: Our findings suggest that an EMT-related gene signature in the tumor epithelium is related to both
stromal activation and escape from disease dormancy in breast cancer. The presence of a late recurrence gene
signature in the primary tumor also suggests that intrinsic features of this tumor regulate the transition of disseminated
tumor cells into a dormant phenotype with the ability to outgrowth as recurrent disease.Introduction
Delayed recurrence, common in breast cancer, is defined
as the clinical appearance of cancer systemically or locally
years (five to twenty-five years) after eradication of the pri-
mary tumor and adjuvant therapy in a patient who has
been clinically disease-free [1]. While patients who have
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unless otherwise stated.have predictably poor clinical outcomes including death
from breast cancer, other patients diagnosed at an early
stage, with small tumors and no evidence of regional
lymph node metastases, can have a late systemic recur-
rence, occurring in as many as one-third of patients if
followed for greater than 10 to 15 years [2-4]. While sys-
tematic cytotoxic or endocrine therapy after curative local
treatment is designed to eradicate occult micrometastases,
these therapies typically reduce metastatic recurrences by
only a third at 10 years [5-8]. The consequences of sys-
temic recurrence are profound, as patients with recurrent
breast cancer usually die of their disease despite second-
or third-line systemic therapies [9,10]. The long intervalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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model of continuous growth of cancer cells [11-15],
but instead suggests a state of tumor dormancy [16].
However, mechanisms that allow for, or lead to, tumor
dormancy remain very poorly understood and require fur-
ther study [4,17-20].
With the intention to predict the risk of disease recur-
rence, several commercially available multigene prognos-
tic assays have been developed, such as Oncotype DX™
[21], PAM50 Breast Cancer Intrinsic Classifier™ [22] and
MammaPrint™ [23]. However, none of these predictors
was designed to classify patients based on their likeli-
hood of developing a late recurrent disease, as the vast
majority of recurrent cases for the development and
testing of these predictors had recurrence within five
years after initial treatment. In this study, we established
a discovery cohort of primary tumors from lymph node-
negative patients who did not receive systemic neoadjuvant
or adjuvant therapy, and conducted a series of recurrence-
free survival analyses to detect differences between late
recurrences (recurrence appeared at or after five years),
which may be due to tumor dormancy features, and early
recurrences (recurrence appeared within five years), which
may be due to aggressive tumor invasion and metastasis
features. We found a distinct set of genes that modulate
either early or late recurrence in breast cancer. Moreover,
late recurrences were associated with a gene expres-
sion signature in the primary tumor consistent with epi-
thelial to mesenchymal plasticity and the occurrence of
tumor-stroma interactions. Lastly, we identified a 51-gene
classifier with these characteristics that was significantly
associated with late distant recurrence in an independent
cohort of 4,767 breast tumor samples. Our results high-
light the importance of analyzing the microenvironment
of primary tumors for biomarker discovery, and to obtain
new insights into the processes that govern breast cancer
dormancy.
Methods
Develop a 4,769 primary breast cancer expression data set
Our previous study developed an approach to compile a
large collection of publicly available gene expression data
[24]. To update this data set, we added 759 additional
samples of clinical outcome data that was available,
and rebuilt this data set. A total of 4,767 breast cancer
gene expression profiles were collected from 25 inde-
pendent data sets (GSE11121, GSE12093, GSE12276,
GSE1456, GSE16391, GSE16446, GSE17705, GSE17907,
GSE19615, GSE2034, GSE20685, GSE21653, GSE22035,
GSE22093, GSE23177, GSE23720, GSE25066, GSE26639,
GSE3494, GSE4922, GSE5327, GSE5460, GSE6532,
GSE7390, GSE9195) that were on the National Center for
Biotechnical Information (NCBI) Gene Expression Omnibus
(GEO; Additional file 1).Primary breast tumor samples were obtained before treat-
ment and gene expression profiles were measured using
Affymetrix U133A or U133 Plus 2.0 expression array
(Affymetrix, Santa Clara, CA, USA). As we described pre-
viously [24], all data were filtered to include those probes
on the HG-U133A platform. Assuming that the signal
from the 69 Affymetrix control probes should be in-
variant, we found the structure in those probes by taking
the first 40 principal components, and then removed the
contribution of those patterns in the expression of genes
using Bayesian Factor Regression Modeling (BFRM) [25].
A Principal Component Analysis (PCA) and Heatmap were
used to confirm data set normalization.
By fitting two normal distributions of mRNA expression
into immunohistochemistry (IHC) positive and negative
groups, we identified bimodal cutoff that represents the
maximum likelihood of IHC status, using samples where
the expression status of human epidermal growth fac-
tor receptor 2 (HER2) (n = 1,579), estrogen receptor (ER)
(n = 3,918) and progesterone receptor (PR) (n = 2,060)
were available [24], and then applied this predictive cutoff
to the samples for which the IHC status of HER2, ER
and PR was not available. For the samples for which
IHC status was available, the final calls for HER2, ER
and PR status were defined according to IHC measure-
ment. For the samples for which IHC status was not avail-
able, the final calls for HER2, ER and PR status were
defined using mRNA expression bimodal cutoffs [24].
Luminal A subtype was defined as ER + and/or PR+,
HER2-; luminal B subtype was defined as ER + and/or
PR+, HER2+; triple-negative breast cancer (TNBC) was
defined as ER-, PR-, HER2-; and HER2 type was defined
as ER-, PR-, HER2 + .
Develop a collection of multi-tissue expression datasets
We developed a data set of 1,042 gene expression profiles
from breast tumors, tumor-adjacent stroma, and ductal
carcinoma in situ (DCIS) from nine independent data
sets (GSE2034, GSE4922, GSE6532, GSE7390, GSE5847,
GSE3893, GSE16873, GSE21422, GSE19615). In this data
set, a total of 763 primary tumor samples obtained from
patients who were not treated with systemic neoadjuvant
or adjuvant treatment were collected from GSE2034 (286
samples), GSE4922 (142 samples), GSE6532 (137 sam-
ples), and GSE7390 (198 samples). Gene expression pro-
files of both tumor epithelium and matched stromal tissue
were obtained from GSE5847 (95 samples). Three data
sets (GSE3893 (10 samples), GSE16873 (40 samples), and
GSE21422 (19 samples) that contained gene expression
profiles of DCIS were also included in this multi-tissue
expression data set, though gene expression of DCIS was
excluded in this study. This multi-tissue expression data
set also contained GSE19615 (115 samples), and the IHC
measured status of HER2, ER and PR from GSE19615 was
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imum likelihood of IHC status. In this data set, we re-
vealed the structure in 69 Affymetrix control probes by
taking the first 15 principal components, and then re-
moved the contribution of those patterns in the expres-
sion of genes using BFRM [25].
Statistical analyses
In addition to the raw expression data, we also obtained
available clinical outcome data from the GEO database,
including recurrence-free survival (the events of both local
and distant recurrence) and distant metastasis-free sur-
vival (the events of first distant metastasis and distant
recurrence). A genome-scale Cox regression survival
analyses was performed using a total of 11,761 known
genes (18,750 probe sets), as described in our previous
study [24]. Gene expression signal was used as continuous
variable, and co-efficiency was applied to determine if
gene expression per se was a direct (overexpression was
associated with poor outcome) or inverse (overexpression
was correlated with good outcome) correlation. For the
recurrence-free survival or distant metastasis-free survival
analyses, patients’ data was censored by the time of the
last follow-up. For the late recurrence-free survival or late
distant metastasis-free survival analyses, patients’ data wasFigure 1 Development of combined data sets. (A) PCA plots of 4,767 e
These plots show the gene expression profiles of the samples plotted on t
samples from the same data set have the same color. If there are batch eff
together. If there are no batch effects, the colors should be mixed.censored by the time of the last follow-up, or the time
of recurrence or metastasis event appearing within five
years. For the early recurrence-free survival or early dis-
tant metastasis-free survival analyses, patients’ data was
censored by the time of the last follow-up, or the time of
recurrence appearing at or after five years.
To assess if the correlation between gene expression and
prognosis was a truly independent prognostic factor, we
conducted an additional genome-scale Cox Proportional-
Hazards Regression (COXPH) survival analyses to quan-
tify the weight of the hazard ratios associated with high
expression and their significance when considered along-
side other clinical variables such as size, grade, nodal sta-
tus, age, HER2, ER and PR, in the whole cohort or in the
relevant subtype of tumors.
Statistical analyses were performed using STATISTICA
11 (Statsoft Inc. Tulsa, OK, USA); R Project for Statistical
Computing (Augasse, Austria); Matlab (Natick, MA,
USA); GraphPad (La Jolla, CA, USA). Two-way hier-
archical clustering was performed using Cluster 3.0
(Tokyo, Japan), and the visualization of microarray data
was carried out using Java Treeview (Boston, MA, USA).
Pathway analysis was conducted using MetaCore (Thomson
Reuters, New York, NY, USA) and Gene Set Enrichment
Analysis (GSEA) [26,27].xpression dataset. (B) PCA plots of multi-tissue expression dataset.
he first two principal components. Each point represents a sample, and
ects, the samples from the same data set (the same color) will cluster
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Distinct characteristics in primary breast tumors with
early or late recurrence
Because clinical dormancy has been defined as the time
(five to twenty-five years) between removing the primary
tumor and relapse [1], we defined late recurrence as recur-
rence (either local or distant recurrence) that occurred five
or more years after initial treatment, and used this clin-
ical scenario as a model to characterize genetic factors
that lead to tumor dormancy. We compiled a collection of
breast tumor gene expression data (n = 4,767) derived
from 25 data sets that were posted on the NCBI GEO
database, using the methods that we previously reportedFigure 2 Correlation between breast cancer molecular subtypes and
metastasis events distribution in different breast cancer subtypes among 4,7
survival (n = 1,847) or distant metastasis-free survival (n = 2,612). For the late re
of last follow-up or death, or the time of recurrence appearing within five yea
censored by the time of last follow-up or death, or the time of recurrence ap[24] (Figure 1; Additional files 1 and 2). We found the
greatest risk for early recurrence or distant metastasis in
patients with HER2-amplified and TNBC tumors, which
led to the poorest recurrence-free survival and distant
metastasis-free survival (Figure 2A). However, there was
no significant difference for late recurrences or distant
metastasis, and late recurrence and distant metastasis oc-
curred in each of molecular disease subtypes (Figure 2B).
To characterize the features of tumors associated with
late recurrence not influenced by variations in treatment,
we focused on a subset of lymph node-negative breast
tumor samples obtained from 743 patients who did not
receive systemic neoadjuvant or adjuvant treatment, andearly or late recurrence. (A) Histograms of recurrence or distant
67 samples. (B) Subtype difference in overall, early or late recurrence-free
currence-free survival analyses, patients’ data was censored by the time
rs. For the early recurrence-free survival analyses, patients’ data was
pearing at/after five years.
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tumor size and basal-like molecular subtype were signifi-
cantly associated with early recurrence, but not late recur-
rence (Table 1). The absence of differences between the
various molecular subtypes in this analysis suggested that
the phenotype of late recurrence is likely a common
phenomenon applicable to all subtypes.
To assess the biological differences in primary tumors
with either early or late recurrence, we developed a multi-
tissue gene expression data set (Figure 1; Additional file 2).
Using the gene expression data of those 743 samples, we
revealed a distinct set of 216 probe sets (189 genes) whose
expression was associated with either early or late recur-
rence (P <0.001, n = 743, Cox-regression survival analysis;
Figure 3A), and this association was not affected by
clinical variables such as size, grade, nodal status, age,
HER2, ER and PR status (P <0.01, n = 438, COXPH)
(Additional file 3).
High degree of epithelial-mesenchymal plasticity in primary
breast tumor was correlated with late recurrence
Using the 216 probe set classifier, a two-way hierarchical
clustering (Centroid Linkage) among those 743 lymph node-
negative breast tumor samples was conducted, which
revealed multiple subgroups with distinct prognostic
characteristics (Figure 3). We found that subgroup G4
was associated with late recurrence (Figure 3), but none of
the breast cancer subtypes was significantly enriched nor
underrepresented in this subgroup (Table 2). Interestingly,
we found TWIST1, a key regulator of EMT [28-30], was
significantly associated with early recurrence (P= 1.92 × 10−4,
COXPH; Additional file 3). However, in subgroup G4 pa-
tients, TWIST1 was co-upregulated with a group of late
recurrence-associated genes (cluster C4), and the collect-
ive effect of this gene cluster was significantly associated
with late recurrence (P = 1.48 × 10−11, Fisher’s exact test;
Table 3). Pathway analysis of gene cluster C4 revealed
both transforming growth factor beta (TGFβ)-dependent
induction of EMT pathway (objects: TWIST1 [28-30],Table 1 Correlation between clinical parameters and early or
Clinical parameter N Early recurrence
P value HR (95% C
HER2 pos. vs. neg. 743 0.1378 1.36 (0.91 -
ER pos. vs. neg. 743 0.0048 0.63 (0.46 -
PR pos. vs. neg. 743 0.0004 0.61 (0.46 -
TNBC TN vs. others 743 0.0031 1.77 (1.21 -
Tumor size ≥2 cm vs. <2 cm 456 0.0008 1.91 (1.31 -
Grade Grade 3 vs. others 438 0.0038 1.87 (1.22 -
Age ≥50 vs. <50 457 0.9933 1.00 (0.69 -
CI: confidence interval; ER: estrogen receptor; HER2: human epidermal growth facto
breast cancer.JAG1 [31]) and human growth factor (HGF)-dependent
inhibition of TGFβ-induced EMT signaling (objects: HGF
[32-35]) were activated in a sample of this subgroup.
To access protein functional process of these EMT-
related signaling this subgroup G4, we carried out GSEA
and found both ‘Regulation of cell differentiation’ and
‘Cell migration’ gene sets were enriched in a sample from
subgroup G4, compared with samples in other sub-
groups (Figure 4). Collectively, results suggested that the
tumors from subgroup G4 had a high degree of epithelial-
mesenchymal plasticity. Since the EMT state has been
associated with quiescence or reduced proliferation [36,37],
the tumor cells with a high degree of epithelial-mesenchymal
plasticity could escape from the primary tumor in a (semi)-
mesenchymal and stem-like state, and could establish a
metastasis at the distant site by reverting to their epithelial
phenotype [38,39].
The significantly higher risk of overall and early recur-
rence in subgroup G2 was correlated with a paucity of
luminal A subtype tumors in this subgroup (Table 2),
and an upregulated gene cluster (C3) enriched with genes
that were directly correlated with early recurrence or in-
versely associated with late recurrence (P <0.0001, Fisher’s
exact test; Table 3). Consistent with our previous finding
[24], activated stress response signaling (network object
HSP90AA1) in gene cluster C3 was correlated with higher
risk of early recurrence (Additional files 3 and 4).
Although patients in subgroup G1 experienced in-
creased risk of late recurrence (Figure 3), this subgroup
was not considered as a desired model for this study, be-
cause subgroup G1 showed an unbalanced distribution
of breast cancer molecular subtypes (Table 2), and the
upregulated gene cluster C2 was not directly correlated
with late recurrence (Table 3).
An activated microenvironment in primary breast tumor
was associated with late recurrence
Because reported experimental evidence suggests that
the microenvironment of a malignant cell may play alate recurrence in 743 dataset
Late recurrence
I) N (event) P value HR (95% CI) N (event)
2.04) 207 0.7788 1.10 (0.57 - 2.13) 80
0.87) 207 0.5023 1.19 (0.72 - 1.97) 80
0.80) 207 0.1027 1.45 (0.93 - 2.28) 80
2.59) 207 0.0974 0.61 (0.34 - 1.10) 80
2.78) 114 0.3184 1.29 (0.78 - 2.12) 67
2.84) 110 0.0692 0.60 (0.35 - 1.04) 61
1.44) 114 0.1144 0.67 (0.41 - 1.10) 66
r receptor 2; HR, hazard ratio; PR: progesterone receptor; TNBC: triple-negative
Figure 3 Analysis of patterns of early or late recurrence-associated genes to define four distinct subgroups of breast cancer. (A) A total
of 208 late recurrence-associated genes (P <0.0001) were selected for overall, early and late Cox regression survival analyses, and P values from
three types of survival analyses are shown. (B) A total of 124 late recurrence-associated genes (P <0.0001) were selected for overall, early and late
Cox regression survival analyses, and P value from these three types of survival analyses are shown. (C) Two-way hierarchical clustering (Centroid
Linkage) of 216 probe sets that were significantly correlated with either early or late recurrence among 789 breast cancer samples, which included
743 lymph node-negative breast tumor samples obtained from patients who did not receive systemic neoadjuvant or adjuvant treatment,
and 46 breast tumor epithelium samples for which gene expression of matched stromal tissue were available. Yellow boxes indicate upregulated
gene cluster (C1 to C4) in related subgroups (G1 to G4). (D) Total, early or late recurrence-free survival was stratified according to breast cancer
subgroups (G1 to G4). Tick marks in Kaplan-Meier estimates distant-metastasis-free survival indicate patients whose data were censored.
P values were calculated using log-rank (Mantel-Cox) test.
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[40-44], we next sought to determine if the subgroup G4
was correlated with a microenvironment activation. We ap-
plied the subgroup classification to a subset of 46 paired
samples [45], for which both tumor epithelium and stromal
cell expression data were available. Using gene expression
data of the tumor epithelium, we assigned these 46 samples
into four subgroups and then compared gene expression
profiles of their matched stromal cells. In this analysis, we
found 48 probe sets whose expression was significantly up-
or downregulated in the stroma of subgroup G4 samples,
compared to samples in all other subgroup (false discovery
rate (FDR) <0.05, Figure 5A, Additional file 5). However,
there was no significant difference in expression of stromal
cell genes among the other three subgroups (FDR <0.05,
comparing subgroups G1, G2, and G3).Owing to the heterogeneity of the cancer genome,
individual genes might have only a modest effect on
the phenotype, or account for only a fraction of the
genetic basis of a phenotype; and as such, when several
interactions occur together, the combined effect becomes
robust and clinically significant [24,46]. We therefore
developed a principal component (SPC1, the first princi-
pal component of the 48 probe sets) comprising the entire
set of genetic alterations identified in stromal of sub-
group G4. Among subgroups with good prognosis (G3),
early recurrence (G2) and late recurrence (G4), mul-
tiple group comparison revealed a linear correlation be-
tween the SPC1 score and time of recurrence (P = 1.05 ×
10−9, ANOVA; Figure 5B), indicating this novel stromal
activation in primary tumor might modulate delayed
recurrence.
Table 2 Distribution of breast cancer subtypes in different subgroups
Subgroup Subtype N Percentage (%) Fisher’s exact test (P value) Odds ratio (OR) 95% confidence interval (95% CI)
G1 Luminal A 85 96.5 4.90E-11 14.3244 4.4797 - 45.8043
Luminal B 1 1.1 0.0143 0.1324 0.0181 - 0.9693
HER2 type 1 1.1 0.0329 0.1574 0.0214 - 1.1559
TNBC 1 1.1 1.12E-06 0.0497 0.0069 - 0.3602
G2 Luminal A 192 62.5 3.88E-04 0.5614 0.4105 - 0.7678
Luminal B 30 9.8 0.0315 1.8715 1.0778 - 3.2496
HER2 type 22 7.2 0.3592 1.3339 0.7378 - 2.4115
TNBC 63 20.5 0.0234 1.5571 1.0631 - 2.2806
G3 Luminal A 144 63.7 0.0195 0.6664 0.4788 - 0.9275
Luminal B 16 7.1 0.6541 0.844 0.461 - 1.5453
HER2 type 17 7.5 0.6311 1.1713 0.6317 - 2.1719
TNBC 49 21.7 0.1185 1.3737 0.9225 - 2.0456
G4 Luminal A 113 79 0.0085 1.7894 1.1567 - 2.7682
Luminal B 8 5.6 0.4771 0.7237 0.3342 - 1.5673
HER2 type 7 4.9 0.5674 0.7476 0.3278 - 1.705
TNBC 15 10.5 0.0255 0.5268 0.2972 - 0.9338
CI: confidence interval; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer.
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microenvironment affect late distant metastasis
Although gene expression profiling has become the major
tool for the study of breast cancer, a large collection of an-
notated tumor stromal data is not current available, which
makes it difficult to validate stromal signatures. Therefore,
we sought to find correlates of stromal activation in the
expression analysis of malignant breast epithelial cells, andTable 3 Distribution of early or late recurrence-associated ge
Cluster Genes associated with Correlation Fisher’s exact tes
C1 Early recurrence direct 1.19 × 10−14
inverse 2.41 × 10−24
Late recurrence direct 0.0002
inverse 0.1872
C2 Early recurrence direct 0.3475
inverse 8.81 × 10−7
Late recurrence direct 0.6402
inverse 0.0744
C3 Early recurrence direct 3.05 × 10−26
inverse 0.0468
Late recurrence direct 0.0057
inverse 9.41 × 10−05
C4 Early recurrence direct 1
inverse 1.50 × 10−08
Late recurrence direct 1.48 × 10−11
inverse 0.3697
CI: confidence interval.determined if tumor-induced changes in the stroma can
serve as a surrogate for stromal activation, including the
likelihood to escape dormancy. We performed a genome-
scale linear regression analysis using the 46 paired tumors
with both epithelium and stromal cell expression data,
and identified 51 genes (57 probe sets) whose expressions
were: (a) associated with SPC1 score (Pearson coeffi-
cient R >0.25); (b) specifically upregulated in subgroup G4nes in different gene clusters
t (P value) Odds ratio (OR) 95% confidence interval (95% CI)
no probe set in C1
89.15 20.82 - 381.84
0.06 0.02 - 0.48
0.21 0.03 - 1.65
0.41 0.09 - 1.92
5.96 2.77 - 12.83
1.28 0.53 - 3.08
no probe set in C2
39.14 17.42 - 87.95
0.02 0.01 - 0.05
0.27 0.10 - 0.73
21.52 2.72 - 170.15
0.98 0.42 - 2.30
no probe set in C4
25.00 9.50 - 65.80
no probe set in C4
Figure 4 Gene Set Enrichment Analysis (GSEA) enrichment plot in subgroup G4 versus other subgroups. (A) GSEA plot for pathways
involved in regulation of cell differentiation. (B) GSEA plot for pathways involved in cell migration.
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t test); and (c) directly correlated with higher risk of recur-
rence among 743 lymph node-negative breast tumor sam-
ples (P <0.01, Cox-regression survival analysis; Additional
file 6). The first principal component (EPC1) that repre-
sents a collection of these 51 genes was significantly corre-
lated with SPC1 score (Pearson coefficient R = 0.5952),
and the distribution of EPC1 scores among different sub-
groups matched the pattern of SPC1 scores (Figure 5B
and C), suggested the 51-gene signature in the tumor epi-
thelium captured tumor-stroma interaction.
The top activated pathways of these 51 genes were
ECM remodeling, fibrosis and EMT signaling (TWIST1,
JAG1, SNAI2 [30]), indicating the correlation between
EMT and stromal activation in primary tumor with high
risk of late recurrence (Additional file 4). Interestingly,
we found a group of secreted proteins from the 51 genes
that have been previously linked to distant metastasis
(Additional file 6), including POSTN [47,48],TNC [49-51],
VCAN [52,53], MRC2 [54,55], ADAM9 [56,57], LIMS1
[58,59] and AEBP1 [60]. For instance, bone metastases
from breast cancer induced by increased expression and
serum secreted level of POSTN [47], and infiltrating
tumor cells need to induce stromal POSTN expression in
the secondary target organ to initiate colonization [48].
TNC expression has been correlated with higher risk
of distant metastasis and local recurrence [49,50], and
breast cancer cells that infiltrate the lungs support their
own metastasis-initiating ability by expressing TNC [51].
VCAN secretion is regulated by the primary tumor,
and the level of VCAN deposited in the peritumoral
stroma at the site of metastasis increased risk of breast
cancer recurrence [52,53]. Our results suggested that fac-
tors of the primary tumor might have a systemic effect on
modulating both local and distant microenvironment,thereby influencing the fate of disseminated tumor cells
(DTCs).
Death from breast cancer is most often due to metastatic
disease rather than the primary tumor [61]. Among those
743 patients who did not received systemic neoadjuvant or
adjuvant treatment, we found that breast cancer mortality
was largely affected by distant metastasis or distant recur-
rence, while local recurrence did not significantly change
the rate of overall survival (Figure 6A). Therefore, we next
sought to determine the association of the 51-gene signa-
ture with distant metastasis/recurrence in a large inde-
pendent cohort of patients, in which we had annotated
distant metastasis data. Using the gene expression datasets
of 4,767 breast cancer samples, we found that the 51-gene
signature (EPC1, Additional file 7A) was significantly up-
regulated in primary tumors obtained from patients who
had late distant metastasis, compared with samples with
early distant metastasis (P = 0.0009, Mann-Whitney U test,
Figure 6B). When samples were grouped according to time
of distant metastasis, the 51-gene signature was signifi-
cantly associated with time of distant recurrence (P =
0.0015, analysis of variance (ANOVA), Figure 6B), indicat-
ing tumor-driven stromal activation influences late disease
recurrence in breast cancer independent of the molecular
disease subtype.
Concordance of epithelial-mesenchymal plasticity and
stromal activation in primary tumors
Although only eight probe sets (14%) from the 51-gene
signature overlapped with probe sets in gene cluster C4,
we found that 25 of 27 probe sets (89.3%) from gene clus-
ter C4 were significantly associated with stromal activation
SPC1 score (Pearson coefficient R >0.25) among the 46
paired tumor epithelium and stroma samples. In an at-
tempt to determine the correlation between the high
Figure 5 Development of a stromal activation-associated 51-gene signature in tumor epithelium. (A) Expression of 48 probe sets that
were significantly up/downregulated in the stroma of subgroup G4 in 46 stromal samples. (B) Identify a principal component (SPC1) in stroma
that represents collection group of 48 probe sets and measures differences of SPC1 score in stroma from different subgroups (n = 46). (C) Identify
a principal component (EPC1) in tumor epithelium that represents the collection of stromal activation-associated genes (51 genes) and measures
differences of EPC1 score in tumor epithelium from different subgroups (n = 46). Differences for each pair-wise comparison were assessed by
Mann-Whitney U test. Boxes represent the 25% to 75% quartiles, lines in the boxes represent the median level, whiskers represent the non-outlier
range, and circles represent the outliers.
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http://breast-cancer-research.com/content/16/1/407degree of epithelial-mesenchymal plasticity of primary breast
tumor (gene cluster C4) and the novel stromal activation
(51-gene signature, EPC1), we developed a principal com-
ponent (C4-PC1) that represents a collection of the 27
probe sets from gene cluster C4 among 4,767 breast
cancer samples (Additional file 7B). We found that the
C4-PC1 score was significantly associated with the 51-
gene signature (Pearson coefficient R = 0.9303, Additional
file 7C), and was significantly correlated with time of dis-
tant recurrence (P = 0.0011, ANOVA, Additional file 7D
and E), indicating the concordance between high-degree
epithelial-mesenchymal plasticity of tumor epithelium and
stromal activation in the primary tumor.
It has been well recognized that the metastatic dissemin-
ation of cancer cells can occur in patients with early-stage
cancer, even prior to initial clinical presentation [39,62];and this has also been seen in experimental models
[63-65]. Yet, features of the primary tumor may not only
control growth and the metastatic capacity of primary
tumors, but also the ability of disseminated disease to
shift into a state of dormancy [66]. While a key role of
epithelial-mesenchymal plasticity in tumor dissemination
has been well established in animal models [38,39], the
functional association of epithelial-mesenchymal plasticity
in primary tumors with a delayed distant recurrence has
not been shown in a large and well-characterized patient
population. In fact, to our knowledge, there have been no
reports on stromal changes in primary tumor that are pre-
dictive of late recurrence. Current study uncovered a dis-
ease subtype and tumor-stage independent gene signature
in primary tumor epithelium that was associated with a
novel stromal activation and a high degree of epithelial-
Figure 6 The 51-gene signature was associated with late distant metastasis. (A) Overall survival was stratified according to events of local
or distant recurrence events among 198 lymph node-negative breast tumor samples obtained from patients who did not receive systemic
neoadjuvant or adjuvant treatment. Tick marks in Kaplan-Meier estimates overall survival indicate patients whose data were censored by
the time of last follow-up. P values were calculated using log-rank (Mantel-Cox) test. (B) Comparing the 51-gene signature score among
patients with early or late distant metastasis in the 4,767 breast tumor dataset. ‘0’ represents samples that had no distant recurrence for
more than 15 years. ‘<5’ and ‘≥5’ represent samples that had early or late distant metastasis. Pair-wise comparison was assessed using
the exact Mann-Whitney U test. Boxes represent the 25% to 75% quartiles, lines in the boxes represent the median level, whiskers represent
the non-outlier range, and circles represent the outliers. (C) Trend increase of the 51-gene signature score according to the time of distant metastasis.
Dots represent average levels. Vertical bars represent 0.95 confidence intervals. Comparison of multiple groups was conducted using analysis of
variance (ANOVA). Pair-wise comparison was assessed using the exact Mann-Whitney U test.
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http://breast-cancer-research.com/content/16/1/407mesenchymal plasticity of the primary tumor epithelium.
The association with late recurrence suggested this 51-
gene signature could predict the transition of tumor cells
to a dormant phenotype with potential outgrowth as re-
current disease.
Conclusions
In this study, we discovered a distinct set of genes that
predicts late recurrence in breast cancer, and also show
that early recurrence (recurrence within five years after
initial treatment) was associated with upregulated stress
response signaling and certain clinical parameters, such
as molecular subtypes, tumor size and grade, while late
recurrence (recurred ≥5 years after initial treatment) was
associated with mesenchymal characteristics of the
tumor epithelium and gene expression alterations in the
adjacent tumor stroma. Though occurrence of late disease
recurrence could be affected by genetic alterations ac-
quired during the long latency of a dormant stage, the
existence of a predictive gene signature for late recur-
rence in the primary tumor suggests that intrinsic featuresof this tumor govern the transition of disseminated tumor
cells into a dormant phenotype with the ability to out-
growth as recurrent disease. Insight into these mecha-
nisms could lead to the identification of novel biomarkers
that indicate whether patients harbor dormant disease,
and help uncover new signaling pathways that can be
therapeutically manipulated to either eliminate dor-
mant tumor cells or to indefinitely maintain them in
this dormant state, thus preventing a progressive meta-
static disease.Additional files
Additional file 1: Summary of 25 data sets. Table summary of 4,767
samples obtained from 25 GEO data sets.
Additional file 2: Heatmaps of data sets normalization. (A) Heatmaps
4,767 expression data set. (B) Heatmaps of multi-tissue expression data set
(n = 1,042). Heatmaps show the expression patterns in the data before and
after normalization. The rows contain the 1,000 genes that exhibit the
highest variance in gene expression profile across the original data set. The
columns contain the samples in the data sets provided. The genes and
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http://breast-cancer-research.com/content/16/1/407samples are in the same order in both heatmaps. Warm colors indicate high
expression of the gene, and cool colors indicate low expression.
Additional file 3: Early or late recurrence associated 216 probe
sets. Table of 216 probe sets and their correlation with disease outcome.
Additional file 4: Significant pathways in selected gene sets. Table
of top activated pathways of selected gene sets.
Additional file 5: Forty-eight probe sets that were up/downregulated
in the stroma of subgroup G4. Table of 48 probe sets that were
up/downregulated in the stroma of subgroup G4.
Additional file 6: Probe sets of 51-gene signature of stromal activation
in primary tumor. Table of probe sets from 51-gene signature of stromal
activation in primary tumor.
Additional file 7: Correlation between gene cluster C4 and late
distant metastasis in the 4,676 sample data set. (A) Develop 51-gene
signature (EPC1) in the 4,767 sample data set. (B) Develop principal
component that represents gene cluster C4 in the 4,767 sample data set.
(C) Pearson correlation between 51-gene signature (EPC1) and the first
principal component of gene cluster C4 (C4-PC1) in the 4,767 sample
data set. (D) Comparing the principal component of gene cluster C4
(C4-PC1) score among patients with early or late distant metastasis.
Differences for each pair-wise comparison were assessed by Mann-Whitney
U test. Boxes represent the 25% to 75% quartiles, lines in the boxes represent
the median level, whiskers represent the non-outlier range, and circles
represent the outliers. (E) Trend increasing of C4-PC1 score according
to the time of distant metastasis. Dots represent average levels. Vertical
bars represent 0.95 confidence intervals. Comparison of multiple groups was
conducted using ANOVA. Pair-wise comparison was assessed using the
exact Mann-Whitney U test.
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